LLM Dergi最新文献

{"title":"Allojeneik Kök Hücre Naklinde Primer ve Sekonder Graft Yetmezliği","authors":"E. Atilla, Pınar Ataca Atilla, Sinem Civriz Bozdağ, Meltem Kurt Yüksel, S. Toprak, Önder Arslan, Meral Beksaç, Muhit Özcan, Günhan Gürman, Pervin Topçuoğlu","doi":"10.5578/LLM.20219903","DOIUrl":"https://doi.org/10.5578/LLM.20219903","url":null,"abstract":"Objective: Primary Engraftment Failure is defined as no evidence of engraftment or hematological recovery of donor cells whereas secondary graft failure refers to the loss of a previously functioning graft. Our aim is to present our cases of primary and secondary graft failure in terms of demographical features, treatments and outcomes. Patients and Methods: From 1992, 13 patients who had second HSCT for graft failure (11 primary/2 secondary) diagnosed at our center were included in our retrospective study. The patient characteristics, survival and therapeutic approaches were evaluated. Results: The median age of the group was 29 (range, 16-64), 9 of them were male. 11 patients had primary graft failure diagnosed as follows: 8 bone marrow failure syndromes (aplastic anemia (AA), fanconi aplastic anemia (FAA), myelodysplastic syndrome (MDS), 2 acute myeloid leukemia (AML), 1 chronic myeloid leukemia (CML). Secondary graft failure was detected in 1 Erden ATİLLA1 İD , Pınar ATACA ATİLLA1 İD , Sinem CİVRİZ BOZDAĞ1 İD , Meltem KURT YÜKSEL1 İD , Selami Koçak TOPRAK1 İD , Önder ARSLAN1 İD , Meral BEKSAÇ1 İD , Muhit ÖZCAN1 İD , Günhan GÜRMAN1 İD , Pervin TOPÇUOĞLU1 İD 1 Ankara Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, Ankara, Türkiye Erden ATİLLA Ankara Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, Ankara-Türkiye Geliş: 22.02.2021 Kabul: 24.02.2021 E-posta: erdenatilla@gmail.com Yazışma Adresi ARAŞTIRMA LLM Dergi 2020;4(4):65-70 • 10.5578/llm.20219903 Makale atıfı: Atilla E, Ataca Atilla P, Civriz Bozdağ S, Kurt Yüksel M, Toprak SK, Arslan Ö ve ark. Allojeneik kök hücre naklinde primer ve sekonder graft yetmezliği. LLM Dergi 2020;4(4):65-70.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123677792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 İlişkili Koagülopati ve Yönetimi","authors":"Hülya Yılmaz, Pervin Topçuoğlu","doi":"10.5578/LLM.20219901","DOIUrl":"https://doi.org/10.5578/LLM.20219901","url":null,"abstract":"","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132451465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multipl Myelom Tanılı Hastaların Sitogenetik Özellikleri ve Prognoza Etkisi","authors":"Taha Ulutan Kars, A. Tekinalp, Hatice Zeynep Dikici, Sinan Demircioğlu, Özcan Çeneli","doi":"10.5578/LLM.20219902","DOIUrl":"https://doi.org/10.5578/LLM.20219902","url":null,"abstract":"Objective: In our study, we aimed to evaluate the effect of cytogenetic features of patients with multiple myeloma (MM) on prognosis in our center. Patients and Methods: The study was designed retrospectively. Age and gender data, laboratory data, subtypes of MM, International Scoring System (ISS) and Revised ISS (R-ISS) stages and cytogenetic characteristic of patients were investigated. Patients were divided into two risk groups according to characteristic of cytogenetics: standart risk and high risk. Survival analysis was examined. Results: 83 of 112 patients diagnosed with multiple myelom whose genetic characteristics were studied were included in the study. 15.7% of these patients had high risk cytogenetics. The 5-year overall survival of all patients was 50%. The 3-year overall survival was 25% in the high-risk group and 75% in the standard-risk group. The median survival was 76 months for standard-risk patients and 28 months for high-risk patients, and this difference was statistically significant (p= 0.004, chi-square: 8.2). Conclusion: Approximately 1/6 of the patients diagnosed with MM have high risk cytogenetics. Overall survival of patients with high-risk cytogenetics was significantly shorter than patients with standard cytogenetics.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127383414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Did Influence Establishment of the National Donor Registry (TURKOK) Our Unrelated Donor Hematopoietic Stem Cell Transplantation Activity? A Retrospective Single Center Analysis","authors":"M. Arat, Nurcan Özçelik, Deniz Gören Şahin, E. Özçelik","doi":"10.5578/llm.69397","DOIUrl":"https://doi.org/10.5578/llm.69397","url":null,"abstract":"Amaç: Allojeneik hematopoietik kök hücre nakli (AHKHN) erişkin hematolojik malignitelerde tedavi edici bir hücresel yöntemdir. Türkiye Kök Hücre Koordinasyon Merkezi (TÜRKÖK), 2015 yılında T.C. Sağlık Bakanlığı tarafından kurulan yeni bir donör kayıt sistemidir. Aktif ve 600’den fazla AHKHN deneyimi olan bir transplant merkezi olarak hipotezimiz, lojistik açıdan daha hızlı erişim ve HLA uyumsuzluğunda kendi vatandaşlarımızın donör olabilmesi dolayısıyla TÜRKÖK’ün nakil kinetiği ve kayıt sistemi temelli sonuçlar üzerinde olumlu etkileri olduğu yönündedir.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131449966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Haploidentical and Unrelated Donor Stem Cell Transplantation in Acute Leukemia Patients","authors":"Deniz Gören Şahin, E. Özçelik, Nurcan Özçelik, Burcu KURT YILDIRIM, F. Hindilerden, R. Küçükkaya, M. Arat","doi":"10.5578/llm.69396","DOIUrl":"https://doi.org/10.5578/llm.69396","url":null,"abstract":"","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126241335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intensive Sequential Chemotherapy with Etoposide, Mitoxantrone and Ctarabine (EMA) as Salvage in Patients with Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation a Retrospective Analysis","authors":"Ayla Gökmen, E. Soydan, Zafer Gökgöz, Ozan Özkumur, Ş. Şen, Ö. Arslan, M. Özcan","doi":"10.5578/llm.68966","DOIUrl":"https://doi.org/10.5578/llm.68966","url":null,"abstract":"alınama-ABSTRACT Objective: Disease relapse following allogeneic stem cell transplantation which depends on the type of the disease and the status at the time of procedure, remains the major cause of treatment failure in patients with acute myeloid leukemia (AML). The optimal treatment strategy for patients with AML relapsing after stem cell transplantation remains contraversial and the prognosis is generally poor. We retrospectively analysed the efficacy of intensive sequential chemoterapy with etoside, mitoxantrone and cytarabine (EMA) to achieve remission in patients with AML relapsing after allogeneic stem cell transplantation in our hematology department. Patients and Methods: Sixteen AML patients relapsing after allogeneic stem cell transplantation who were treated with EMA chemoterapy between 2015-2018 were analysed retrospectively. Results: Complete remission was achieved in 7 (43.7%) of 16 patients. All patients suffered grade 4 neutropenia, thrombocytopenia and neutropenic fever. Five (31.3%) patients were died during treatment due to infection. Further treatment with donor cell based therapies was given in seven patients who achieved complete remission after EMA. One-year survival rates in responding patients was %57. Conclusion: Long term survival can be achieved with donor cell based treatment strategy in patients with AML relapsing after stem cell transplantation. Induction of complete remission with cytoreductive therapy can influence the survival of patients who are suitable for intensive therapy. Intensive sequential EMA chemoterapy is an efficacious option to induce remission in theese patients.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124249637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Consultation Results for Histopathological Diagnosis in Hematological Malignancies","authors":"C. Cansız Ersöz, İ̇lker Ufuk Sayici, C. Dogan, M. Durgun, Gizem Coşkun, G. Kaygusuz, Zeynep BIYIKLI GENÇTÜRK, Ferda Demir, M. Özcan, I. Kuzu","doi":"10.5578/LLM.68474","DOIUrl":"https://doi.org/10.5578/LLM.68474","url":null,"abstract":"Objective: In addition to morphological methods, immunohistochemistry (IHC) and molecular investigations are necessary for the diagnosis and determination of prognostic criteria of lymphomas. The aim of this study is to determine the importance of second opinion from the centers experienced in hematopathology, the rate of diagnostic changes, the medical and economic results caused by these diagnostic changes. Patients and Methods: The report of 4672 patients who were examined for the second opinion in the Department of Pathology between January 2006 and June 2010, searched from records Cevriye CANSIZ ERSÖZ1, İlker Ufuk SAYICI1, Cansu DOĞAN1, Meltem DURĞUN1, Gizem COşkUN1, Gülşah kAYGUSUZ1, Zeynep BIYIklI GENçtüRk2, Ferda DEMİR3, Muhit ÖZCAN3, Işınsu kUZU1 1 Ankara Üniversitesi Tıp Fakültesi, Tıbbi Patoloji Anabilim Dalı, Ankara, Türkiye 2 Ankara Üniversitesi Tıp Fakültesi, Tıbbi İstatistik Anabilim Dalı, Ankara, Türkiye 3 Ankara Üniversitesi Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye Uzm. Dr. Cevriye Cansız Ersöz Ankara Üniversitesi Tıp Fakültesi, Tıbbi Patoloji Anabilim Dalı, Ankara-Türkiye Geliş: 07.07.2019 Kabul: 12.07.2019 E-posta: cevriye80@yahoo.com Yazışma Adresi ARAŞTIRMA LLM Dergi 2019;3(2):31-37 • 10.5578/llm.68474 Makale atıfı: Cansız Ersöz C, Sayıcı İU, Doğan C, Durğun M, Coşkun G, Kaygusuz G, Bıyıklı Gençtürk Z, Demir F, Özcan M, Kuzu I. Hematolojik malignitelerde histopatolojik tanı amaçlı konsültasyon sonuçlarının değerlendirilmesi. LLM Dergi 2019;3(2):31-7. Hematolojik Malignitelerde Histopatolojik Tanı Amaçlı Konsültasyon Sonuçlarının Değerlendirilmesi LLM Dergi 2019;3(2):31-37 32 GİRİŞ Lenfoid neoplaziler; farklılaşmanın değişik aşamasındaki B hücre, T hücre ve natural killer (NK) hücrelerinin klonal proliferasyonu ile meydana gelir. Bu neoplaziler farklı ve değişken klinik, patolojik ve genetik özellikler göstermektedir. Sınıflamada bu hastalıkların; klinik, patolojik ve genetik dahil olmak üzere bilinen tüm özellikleri temel alınmaktadır. Gelişmelere paralel olarak da lenfoma sınıflaması sürekli güncellenmekte ve değişiklikler ortaya çıkmaktadır. Dünya Sağlık Örgütü (DSÖ)’nün 2016 yılında güncellenen en son lenfoma sınıflamasında çok sayıda farklı lenfoma grupları tanımlanmıştır. Bu sınıflamada; lenfoid neoplazilerin epidemiyolojik, morfolojik, immünofenotipik ve genetik özelliklerinin belirlenmesi tanıda önem taşımaktadır. Neoplazilerin hiçbiri için spesifik bir antijenik belirleyici yoktur. Bu nedenle doğru tanı için morfolojik özelliklerin antijenik panel ile birlikte değerlendirilmesi, yorumlanması bazen moleküler verilerin eklenmesi gereklidir. Bütün gelişmelere karşın birbiriyle örtüşen özellikler gösteren ve kesin ayırıcı tanı yapılamayan sınır olgular hala bulunmaktadır. Lenfomaların büyük kısmı, en hızlı ilerleyen kanser türlerinden biri olmasına karşın, tedavi başarısı oldukça yüksektir. Günümüzde lenfomanın patogenezi ile ilgili yapılan çalışmalar ve bunların tedavisinde her geçen gün kullanıma giren h","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115203160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the Decrease in the Immunoglobulin Level Important After First Cycle Chemotheraphy of the Newly Diagnosed Multiple Myeloma Patients?","authors":"E. Akyazi, E. Kelkitli, M. Turgut","doi":"10.5578/LLM.68518","DOIUrl":"https://doi.org/10.5578/LLM.68518","url":null,"abstract":"Objective: Multiple myeloma (MM) is a malignant disease which develops due to the proliferation of only one clonal plasma cell. Treatment response can influence the long term results of the disease and assessing this response as early as possible is important in determining treatment strategies. The purpose of this study was to find out whether the decrease in immunoglobulins, following a cycle of chemotheraphy could predict the rate of treatment response, progression free survival (PFS) and overal survival (OS). Patients and Methods: One hundred and fifty-three MM patients who had been newly diagnosed our clinic between January 2007-February 2016 and who had been followed up in our center were evaluated retrospectively. The patients treatments, treatment responses, survival and progression-free survival times were found. The difference between immunoglobulin levels at the time of diagnosis and immunoglobulin levels at the end of first cycle was found. These rates were compared with treatment response, PFS and OS. Elif AKYAZI1, Engin KELKİTLİ2, Mehmet TURGUT2 1 Sağlık Bilimleri Üniversitesi Samsun Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Samsun, Türkiye 2 Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, Samsun, Türkiye Doç. Dr. Engin KELKİTLİ Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, Samsun-Türkiye Geliş: 10.06.2019 Kabul: 17.07.2019 E-posta: ekelkitli@gmail.com Yazışma Adresi ARAŞTIRMA LLM Dergi 2019;3(2):38-44 • 10.5578/llm.68518 Makale atıfı: Akyazı E, Kelkitli E, Turgut M. Yeni tanı multipl miyelom hastalarında ilk kür tedavi sonrası immünoglobulin düzeyindeki azalma önemli mi? LLM Dergi 2019;3(2):38-44.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126810898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Approaches Targeting Glucose, Glutamine and Lipid Metabolism in Multiple Myeloma","authors":"B. Doğan, Cansu ÖZAL COŞKUN, R. DİZ KÜÇÜKKAYA, Engin Kaptan","doi":"10.5578/LLM.68535","DOIUrl":"https://doi.org/10.5578/LLM.68535","url":null,"abstract":"Multiple changes in the cancer-causing genes convert the normal cells into cancer phenotypes characterized by prolonged proliferative signalling, resistance to cell death, stimulation of vascular growth for oxygen and nutrient supply (angiogenesis), active invasion, and metastasis. Some of these phenotypic changes are metabolic adaptations such as increased glycolysis or glutaminolysis. It is possible to encounter these adaptations in many cancers including multiple myeloma (MM) which is defined as malignant proliferation of bone marrow by clonal plasma cells. In recent years, it has been remarkable that studies have focused on understanding the metabolic adaptation processes of cancer cells and thus retard the progression of the tumour and develop treatment strategies that result in a positive clinical outcome. Increased glycolysis and glutaminolysis are prominent metabolic adaptations in MM cells compared to healthy cells. However, studies with MM are more limited than other malignancies. In this review, the differences in cellular oncoproteins, metabolites and enzymes that contribute to metabolic adaptations in MM cells and treatment approaches targeting these processes will be discussed.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126751054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paroxysmal Nocturnal Hemoglobinuria Refractory Anemia","authors":"Demet Çekdemi̇r, H. Ergenç, A. Uçar, Cengiz Karacaer, Z. Kahyaoğlu, Y. Çekdemir, Mehmet Gündüz, A. Tulunay, H. Cinemre, A. Tamer","doi":"10.5578/LLM.68078","DOIUrl":"https://doi.org/10.5578/LLM.68078","url":null,"abstract":"Objective: To reveal the frequency of paroxysmal nocturnal hemoglobinuria (PNH) in cases followed up with the diagnosis of refractory anemia. Patients and Methods: Patients with refractory anemia admitted to our hematology outpatient clinic were included in the study. Serum iron, ferritin, and total iron binding capacity levels were assessed. In all patients, bone marrow biopsy and aspiration were performed. The PNH clone was evaluated according to the defect in CD59 expressions of neutrophils. Results: A total of 18 (9 males, 9 females) refractory anemia patients (mean age, 76.4 years) were included in the study. Of the 18 patients, the. The PNH clone was not detected in any of the patients included in the study. Demet ÇEKDEMİR1, Hasan ERGENÇ2, Ayşenur UÇAR3, Cengiz KARACAER3, Zeynep KAHyAoğlU4, yasin Ertuğ ÇEKDEMİR5, Mehmet GÜNDÜZ6, Aysin TUlUNAy7, Hakan CİNEMRE8, Ali TAMER8 1 Anadolu Sağlık Merkezi, Hematoloji Bölümü, Kocaeli, Türkiye 2 Ayancık Devlet Hastanesi, İç Hastalıkları Kliniği, Sinop, Türkiye 3 Sakarya Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Sakarya, Türkiye 4 Sakarya Eğitim ve Araştırma Hastanesi, Patoloji Kliniği, Sakarya, Türkiye 5 Dokuz Eylül Üniversitesi Tıp Fakültesi, Radyoloji Anabilim Dalı, İzmir, Türkiye 6 Ankara Atatürk Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, Ankara, Türkiye 7 Marmara Üniversitesi Tıp Fakültesi Vakfı İktisadi İşletmesi, Hematoloji İmmünoloji Anabilim Dalı, İstanbul, Türkiye 8 Sakarya Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Sakarya, Türkiye Uzm. Dr. Demet ÇEKDEMİR Anadolu Sağlık Merkezi, Hematoloji Bölümü, Kocaeli-Türkiye Geliş: 26.01.2019 Kabul: 22.03.2019 E-posta: demetcekdemir@yahoo.com.tr Yazışma Adresi ARAŞTIRMA LLM Dergi 2019;3(2):28-30 • 10.5578/llm.68078 Makale atıfı: Çekdemir D, Ergenç H, Uçar A, Karacaer C, Kahyaoğlu Z, Çekdemir YE, Gündüz M, Tulunay A, Cinemre H, Tamer A. Refrakter anemi hastalarında paroksismal noktürnal hemoglobinüri klonu. LLM Dergi 2019;3(2):28-30.","PeriodicalId":354438,"journal":{"name":"LLM Dergi","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126406807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}